- Home
- HL vs BBIO Comparison
HL vs BBIO Comparison
Compare HL & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HL | BBIO |
|---|---|---|
| Founded | 1891 | 2015 |
| Country | United States | United States |
| Employees | 1865 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8B | 12.7B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HL | BBIO |
|---|---|---|
| Price | $16.46 | $77.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 25 |
| Target Price | $21.13 | ★ $86.33 |
| AVG Volume (30 Days) | ★ 27.6M | 2.8M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $502,076,000.00 |
| Revenue This Year | $4.92 | $89.45 |
| Revenue Next Year | N/A | $73.78 |
| P/E Ratio | $44.94 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $5.62 | $42.09 |
| 52 Week High | $34.17 | $84.94 |
Technical Indicators
Market Signals| Indicator | HL | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 74.69 |
| Support Level | $16.46 | $62.39 |
| Resistance Level | $17.81 | $79.57 |
| Average True Range (ATR) | 0.76 | 2.43 |
| MACD | 0.20 | 1.15 |
| Stochastic Oscillator | 71.34 | 90.85 |
Price Performance
Historical ComparisonAbout HL Hecla Mining Company
Hecla Mining Co produces and explores silver, gold, zinc, and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, and Casa Berardi. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada, the United States, and Mexico, and it derives a majority of its revenue from the United States.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.